Effectiveness of the flash glucose monitoring system in preventing severe hypoglycemic episodes and in improving glucose metrics and quality of life in subjects with type 1 diabetes at high risk of acute diabetes complications

期刊论文
出版模式：

开放获取
发表日期：

2024年6月4日

查看全文

Alessandra Dei Cas,
Raffaella Aldigeri,
Giulia Bellei,
Davide Raffaeli,
Paolo Di Bartolo,
Alessandra Sforza,
Giulio Marchesini,
Anna Vittoria Ciardullo,
Valeria Manicardi,
Maurizio Bianco,
Marcello Monesi,
Anna Vacirca,
Maria Cristina Cimicchi,
Paola Anna Sordillo,
Mattia Altini,
Federica Fantuzzi,
Riccardo C Bonadonna,
Maria Grazia Magotti,
Silvia Haddoub,
Elena Turola,
Clelia Di Seclì,
Diletta Ugolotti,
Francesca Marchignoli,
Maria Letizia Petroni,
Gilberto Laffi,
Rossella D’Urso,
Elena Malchiodi,
Elisa Manicardi,
Lisa Bonilauri,
Rita Manini,
Costanza Farabegoli,
Patrizia Scolozzi

摘要

Aims

To assess the effectiveness of the intermittent-scanned continuous glucose monitoring (isCGM) system in preventing severe hypoglycemic episodes and in improving glucose parameters and quality of life.

Methods

Four hundred T1D individuals were enrolled in a prospective real-word study with an intermittently scanned continuous glucose monitoring device during the 12-months follow-up. The primary endpoint was the incidence of severe hypoglycemic events.

Results

82% of subjects were naïve to the use of the device (group A) and 18% were already wearing the system (group B). The cumulative incidence of severe hypoglycemia (SH) at 12 months was 12.06 per 100 person-year (95% CI: 8.35–16.85) in group A and 10.14 (95% CI: 4.08–20.90) in group B without inter-group differences. In group A there was a significant decrease in SH at 12 months compared to 3 months period (p = 0.005). Time in glucose range significantly increased in both groups accompanied with a significant decrease in glucose variability. HbA1c showed a progressive significant time-dependent decrease in group A. The use of the device significantly improved the perceived quality of life.

Conclusion

This study confirmed the effectiveness of the isCGM in reducing hypoglycemic risk without glucose deterioration, with potential benefits on adverse outcomes in T1D individuals.

Trial registration: ClinicalTrials.gov registration no. NCT04060732.